CTLA4 and neoplasm: Kondo et al. demonstrated that the MIH63 antibody in combination with the CTLA-4, but not PD-1, antibody marginally slowed tumor growth in a SCCVII transplantable tumor model (SCCVII: a poorly immunogenic and immunotherapy-resistant SCC model), relative to CTLA-4 or PD-1 monotherapy alone [86].